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Abstract 
Cerebral vasospasm is a serious complica-
tion of ruptured aneurysm. In order to avoid
short-  and  long-term  effects  of  cerebral
vasospasm, and as there is no single or optimal
treatment modality employed, we have insti-
tuted a protocol for the prevention and treat-
ment  of  vasospasm  in  patients  suffering
aneurysmal  sub-arachnoid  hemorrhage
(SAH). We then reviewed the effectiveness of
this  protocol  in  reducing  the  mortality  and
morbidity rate in our institution. In this study
we present a retrospective analysis of 52 cases.
Between March 2004 and December 2008 52
patients  were  admitted  to  our  service  with
aneurysmal  SAH.  All  patients  commenced
nimodipine,  magnesium  sulphate  (MgSO4)
and triple H therapy. Patients with significant
reduction in conscious level were intubated,
ventilated and sedated. Intracranial pressure
(ICP)  monitoring  was  used  for  intubated
patients. Sodium thiopental coma was induced
for patients with refractory high ICP; angiogra-
phy  was  performed  for  diagnosis  and  treat-
ment.  Balloon  angioplasty  was  performed  if
considered necessary. Using this protocol, only
13  patients  (25%)  developed  clinical  vaso-
spasm. Ten of them were given barbiturates to
induce coma. Three patients underwent trans-
luminal  balloon  angioplasty.  Four  out  of  52
patients (7.7%) died from severe vasospasm, 3
patients (5.8%) became severely disabled, and
39 patients (75%) were discharged in a condi-
tion considered as either normal or near to
their pre-hemorrhage status.  Our results con-
firm  that  the  aforementioned  protocol  for
treatment of cerebral vasospasm is effective
and can be used safely.
Introduction
Cerebral vasospasm (CV) is the most signif-
icant cause of high mortality and morbidity in
patients suffering aneurysmal sub-arachnoid
hemorrhage (SAH); but it may also occur after
head  injury.
1 The  precise  pathogenesis  of
vasospasm is still poorly understood but seems
to be related to the products of the erythrocyte
breakdown.
2 This  entity  is  a  multifactorial
problem and is highly correlated with poor clin-
ical grade at presentation and the amount of
blood in the subarachnoid space. The site of
the  aneurysm,  the  presence  of  hypotension,
hyponatremia,  hypovolemia,  hyperthermia,
high  intracranial  pressure,  intraventricular
hemorrhage, the use of antifibrinolytic agents,
smoking, and the age of the patient are also
considered as risk factors for CV.
3-6
Typically, CV occurs on about the fourth day
after  SAH  and  usually  peaks  between  seven
and ten days. Diffuse or worsening headache
with irritability are usually the initial symp-
toms; altered level of consciousness and the
appearance of a new focal neurological deficit
are  other  hallmarks  of  clinical  vasospasm.
7
Multimodal  treatments  for  CV  have  been
adopted by various institutions, but no consen-
sus has yet been reached on the optimal proto-
col.
8 Here we introduce the protocol used in
our  practice  to  deal  with  patients  suffering
from ruptured aneurysm and at risk of develop-
ing clinical vasospasm, and then discuss the
results  obtained  from  applying  this  protocol
over the last four years. In comparison with
other  protocols  used  we  concluded  that  our
protocol is safe and effective.
9,10
Materials and Methods
The study was approved by the ethical com-
mittee  for  human  research  (IRB)  at  Jordan
University  of  Science  and  Technology.  Our
study population consisted of 52 patients treat-
ed only for aneurysmal SAH in King Abdullah
University Hospital between March 2004 and
April 2008 (Table 1).  The diagnosis was based
on  the  clinical  presentation  of  ruptured
aneurysm, a CT scan positive for SAH, and the
presence of aneurysm on digital subtraction
angiography (DSA). Lumbar puncture to check
for erythrocytes or xanthochromia in the CSF
was also considered in patients with a history
highly suggestive of ruptured aneurysm and a
negative CT scan for SAH. Patients with head
trauma, unruptured aneurysm or a DSA nega-
tive  for  aneurysm  were  excluded  from  this
study.  
The  World  Federation  of  Neurosurgical
Society (WFNS) Glasgow Coma Scale (GCS)
grading  system
3 was  applied  to  assess  all
patients  neurologically.  Thirty-  two  patients
(61.5%) were classified as grade 1, 9 patients
(17.4%) as grade 2, and 5 patients (9.6%) as
grade 3; the remaining (11.5%) were grades 4
and 5. Of these, one patient evolved from grade
1 to 5 before she arrived at our service after re-
bleeding.
The Fisher grading system was applied to the
study group to correlate the amount of blood
seen  on  the  CT  scan  with  the  risk  of
vasospasm.
4 One patient ranked grade 1 as the
CT scan was negative for bleeding and the CSF
was positive for xanthochromia, the majority of
patients were categorized grade 2 and 3, and
only 3 patients (5.8%) were assessed as Fisher
grade 4. The standard procedure in this institu-
tion is for early aneurysm repair by coiling or
clipping  within the first three days of rupture.
Most  patients  in  the  study  underwent  early
repair except 6 (11.5%) in whom the aneurysm
was repaired late (between days 12 and 14) as
the patients arrived at our hospital service two
days after the ictus; in those patients we chose
to repair the aneurysm after the peak of the
vasospasm  when  coiling  was  not  applicable.
The cranial orbito-zygomatico-pterional trans-
sylvian approach was selected to deal with 18
patients (34.6%) for direct clipping; while the
patient with giant aneurysm (1.9%) underwent
the same approach for resection and aneurys-
morrhaphy  with  reinforcement.  Endovascular
coiling  was  effected  in  31  patients  (59.6%)
including those with basilar tip aneurysm. Two
patients  (3.9%)  had  no  intervention  as  they
were in a moribund condition.
Protocol used for the management
of cerebral vasospasm
Once the diagnosis of aneurysmal SAH was
made, the following protocol was applied from
the time of admission as a preventive measure
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intensive  care  unit.  Intravenous  fluids  were
commenced at a rate of 1.7 mL/kg/h of normal
saline 0.9% versus glucose water 5%. Systolic
blood pressure was maintained between 120
and 160 mmHg and raised up to 180 as indicat-
ed in patients with secured aneurysm. Oxygen
saturation was maintained at >95% for at least
14  days  and  longer  if  vasospasm  developed.
Nimodipine was given for 21 days as an intra-
venous infusion of 20 mcg/kg/h from the day of
admission for up to two weeks, and then con-
tinued at 60 mg/4h orally for another week if
there was no evidence of vasospasm. In the
presence of vasospasm, nimodipine was con-
tinued  intravenously  for  21  days.  MgSO4 20
mEq/L in 0.9% Normal saline was also given to
maintain  the  serum  magnesium  double  the
normal level between 1.5 and 2 mmol/L for 10-
14 days (average 40-80 mEq/d).
When patients developed symptoms sugges-
tive of clinical vasospasm, a non-contrast CT
scan  was  repeated  to  rule  out  re-bleeding,
hydrocephalus  cerebral  edema,  or  ischemic
changes. Patients with a significant decline in
level of consciousness (GCS fall of more than
two  points)  were  intubated,  ventilated  and
sedated using morphine and midazolam at a
rate  of  5  mg/h  each.  Intracranial  pressure
(ICP) was monitored on all intubated patients.
For all patients with new symptoms sugges-
tive of  vasospasm, with a negative CT scan
and  no  metabolic  disorders  to  explain  the
symptoms, cerebral angiography was repeated
to confirm the diagnosis and to reverse the
narrowed segments with selective injection of
vasodilators (papaverine vs. nimodipine) into
the  cerebral  arteries  in  spasm.  Intraarterial
vasodilators  was  repeated  for  patients  with
persistent  vasospasm.  Transluminal  balloon
angioplasty was also used when necessary in
patients with symptomatic proximal vasospas-
tic segments who did not respond to the med-
ical treatment.
Although not a specific treatment option for
CV,  administration  of  barbiturates  has  been
applied in the management of patients in our
department who continued to display refracto-
ry  cerebral  vasospasm  with  a  significant
decline in conscious level (GCS below 9/15)
and intractable high ICP to provide adequate
cerebral  protection  during  vasospasm.  When
required,  intravenous  sodium  thiopental
(STP) was used at a rate of 3-4 mg/kg/h after a
bolus dose of 10 mg/kg over one hour, with
therapeutic endpoint being control of ICP or its
side effects such as sepsis or hypotension. 
Results
Using  this  protocol,  13  (25%)  of  the  52
patients admitted with aneurysmal subarach-
noid hemorrhage had symptomatic vasospasm
requiring  aggressive  treatment  (8  males,  5
females;  male:female  ratio  1.6:1).  Three
patients were Fisher grade 2, 7 patients grade
3, and the rest grade 4.  The anterior commu-
nicating  artery  was  the  site  of  ruptured
aneurysm  in  8  patients  with  clinical  vaso-
spasm (Figure 1), while the posterior commu-
nicating, terminal carotid and middle cerebral
arteries  were  the  origin  in  5  cases.    Six
patients required intraarterial vasodilators for
prolonged  vasospasm.  Transluminal  balloon
angioplasty  was  successfully  performed  in  3
patients  (Figure  2A  and  B).    Ten  patients
received  barbiturates;  administration  was
stopped early in 2, the first a young woman
who developed fixed dilated pupils on the fol-
lowing day and the other a patient who sus-
tained a high fever with leukocytosis after two
days.  He  continued  to  decline  until  he  died
from vasospasm three days later. STP was used
for 1-5 (average 3.5) days.
Patient outcomes
Four, all of whom had anterior communicat-
ing artery aneurysm, of the 52 patients (7.7%)
died of severe vasospasm. Another 6 patients
(11.5%) died of other causes, 3 from re-bleed-
ing, 2 from pulmonary embolism and one from
sepsis,  giving  an  overall  mortality  rate  of
19.2%.  Three  patients  (5.8%)  survived  with
significant disability requiring ongoing nurs-
ing  care  (Figure  3A  and  B).  The  remaining
patients (75%) were discharged in either nor-
mal  condition  or  with  minor  neurological
deficit. Two patients experienced mild hemi-
paresis and sensory changes which recovered
well  over  time  (Table  3).  However,  some
patients  experienced  variable  clinical  signs
identical to those of symptomatic vasospasm.
One developed a progressive decline in con-
scious level; CT scan revealed active communi-
cating  hydrocephalus  but  he  made  a  good
recovery after placement of a ventriculo-peri-
toneal  shunt.    Another  patient  became
depressed  with  behavioral  changes.  Invest-
igative tests resulted normal and she respond-
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Figure  1.  DSA  (AP)  views  of  a  20  year  old  woman  presenting  with  symptomatic
vasospasm, showing severe vasospasm. The arrow indicates the coiled anterior communi-
cating  artery  aneurysm.  Although  all  treatment  options  were  used,  she  continued  to
decline until death.
Table 1. Demographic details.
Sex  Males 28 (53.8%)
Females 24 (46.2%)      
Age  Mean 45
Range 20-72
Table  2.  Distribution  of  patients  with
aneurysmal SAH by artery of origin.
Artery of origin Number of 
patients
(% of total)
Anterior comunicating 22 (42.3)
Posterior communicating 15 (28.8)
Middle cerebral  5 (9.6)
Terminal internal carotid  4 (7.7)
Ophthalmic  2 (3.9)
Supraclinoid internal carotid 1 (1.9)
Multiple locations  1 (1.9)
Basilar tip  2 (3.9)
Table 3. Results obtained from the proto-
col for cerebral vasospasm used to manage
52  patients  suffering  from  aneurysmal
subarachnoid hemorrhage.
Outcome % of total 
Symptomatic vasospasm 13 (25.0)
Severe disability 3 (5.8)
Mild disability 2 (3.9)
Mortality rate from vasospasm  4 (7.7) ed well to antidepressant medication.  Another
developed  grand  mal  seizures  after  his  full
recovery  from  severe  vasospasm  and  he  is
maintained on anticonvulsant medications.
Discussion
Symptomatic  cerebral  vasospasm  is  the
most significant cause of high mortality and
morbidity  in  patients  suffering  aneurysmal
SAH.  It  ranges  in  severity  from  mild  and
reversible to severe, leaving disabling deficits
from  ischemic  changes  in  7%  of  affected
patients. Vasospasm can be severe enough to
cause infarction and death in another 7% of
patients.  Angiographic  vasospasm  after  rup-
tured aneurysm occurs in 30-70% of patients,
while symptomatic vasospasm is seen in about
one third of cases.
11
The  etiology  of  vasospasm  is  still  under
debate; the mechanism is related to the arteri-
al blood clot and its spasmogenic products.
12
Oxyhemoglobin and free radicals produced by
lysed red cells result in noxious effects on the
endothelial  cells  and  smooth  muscle  of  the
arterial wall. An influx of calcium ions and pro-
tein kinase C are implicated in the release of
vasoconstricting  substances,  which  leads  to
significant structural changes in the arterial
wall including smooth muscle and myofibrob-
last  proliferation,  cellular  necrosis,  intimal
hyperplasia and fibrosis, resulting in vasocon-
striction.  Removal  of  the  blood  clot  and  its
products has been proposed to prevent these
changes but the efficacy of this treatment has
not been proven.  However, calcium concentra-
tion  in  endothelial  and  smooth  muscle  cells
may play a part in the pathogenesis of cerebral
vasospasm.
13-18 Increased  nitric  oxide  in  the
CSF may play a role in the development of CV
through a free radical-mediated injury of the
endothelial cell membrane.
19
One  of  the  most  recent  vasoconstricting
mediators is endothelin (ET-1) which is pro-
duced by the endothelial cells. It interacts with
endothelin receptors located on smooth mus-
cle cells and triggers vasoconstriction and pro-
liferation  of  endothelial  and  smooth  muscle
cells.
20,21 Recent studies have focused on dis-
covering  an  effective  antagonist  to  the
endothelin receptors to block the cascade of
the arterial wall reactions.
22 Nevertheless, pro-
longed CV can be explained by the biomechan-
ical and phenotypic reactions in response to
SAH rather than from myogenic changes in the
arterial wall.
23,24
Numerous  diagnostic  tools  and  treatment
options of vasospasm now exist. Most recent
treatment modalities utilized can be grouped
into  direct  or  indirect  pharmaceutical  and
mechanical  vasodilators  and  neuroprotective
agents.
24-26 Further clinical trials are still need-
ed  to  establish  standard  guidelines  for  the
management  of  CV.  Several  diagnostic  tech-
niques  have  been  used  to  predict  CV.
Computed tomography scanning (CT) is con-
sidered  an  important  initial  method  for  the
prediction of vasospasm and its consequences.
The large amount of blood on the initial CT
scan  is  known  to  be  a  prognosticator  of
ischemia  or  even  infarction  from  arterial
vasospasm.
4 Transcranial doppler sonography
(TCD) can detect increased velocities in the
basal segments of the anterior or posterior cir-
culations. A rapid rise in velocity in the artery
is  usually  associated  with  symptomatic
vasospasm.  Although  it  is  feasible  and  non-
invasive, TCD is less accurate than cerebral
angiograghy  in  confirming  vasospasm.  It
should  be  used  to  follow  the  progress  of
vasospasm.
27,28
Although it is invasive, cerebral angiogra-
phy is still the most accurate and standard tool
for the diagnosis of vasospasm in addition to
its  value  for  endovascular  treatment.
28 New
technologies such as CT perfusion scan, single
photon  emission  computed  tomography
(SPECT)  and  magnetic  resonance  perfusion
and diffusion scans may be employed to identi-
fy early ischemic foci in the brain before clini-
cal vasospasm arises.
12
Triple-H therapy consisting of hypervolemia,
hemodilution and hypertension is a treatment
designed to enhance cerebral blood flow (CBF)
in ischemic zones and lower blood viscosity. It
has  been  shown  to  offer  benefits  in  many
series, but it may not reduce overall morbidity
and mortality. Increased blood volume can be
obtained by using volume expanders or crystal-
loid fluids. Hemodilution can frequently occur
passively with an optimum hematocrit goal of
between 30% and 33% without affecting O2car-
rying  capacity.  Elevating  the  systemic  blood
pressure can be introduced by volume expan-
sion or pressors. Inducing hypertension may
be  risky  with  an  unsecured  aneurysm.  It  is
necessary  to  monitor  hemodynamics  via
appropriate  indwelling  catheters.  The  end
point of triple-H therapy is significant brain
edema or large infarction.
29-31 
The calcium entry blocking agent nimodip-
ine  has  preferential  cerebrovascular  dilating
effects, with potential use in the therapy and
prevention of CV after aneurysmal SAH as it
protects  against  delayed  ischemic  damage.
Continuous  infusion  of  nimodipine  (20
mcg/kg/h) is initially given on admission and
continued for 21 days. However, oral nimodip-
ine (60 mg every four hours) can be continued
for  21  days  in  the  absence  of  clinical
vasospasm.  Nimodipine  has  been  shown  to
decrease the incidence of CV and improve neu-
rological  outcome.
32-34 Selective  intraarterial
nimodipine treatment is currently being sug-
gested as a safe and effective treatment for
CV.
35-36 Intraoperative nimodipine infusion has
also  been  trialled  to  prevent  CV  during
intracranial aneurysm surgery with promising
Article
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Figure 2. (a) DSA (AP) views pre- and post balloon angioplasty of a young patient suffer-
ing severe vasospasm. Narrowing of the anterior cerebral artery can be seen in the pre- bal-
loon angioplasty figures (one arrow); the same artery dilated post balloon angioplasty (2
arrows). (b) CT scan of the same patient after recovery from cerebral vasospasm showing




37 More recently, interest has emerged
in the use of magnesium sulphate (MgSO4) as
a  neuroprotectant  in  obstetric  patients  with
eclampsia  and  as  a  cerebral  vasodilator  for
vasospasm. The role of MgSO4 in preventing
vasospasm  is  questionable,  but  it  may  aug-
ment  CBF  by  inducing  vasodilatation.
38
Evidence obtained from experimental models
of brain injury, stroke and SAH indicates that
magnesium ions play a significant role as neu-
roprotective  agents.  Continuous  infusion  of
high-dose magnesium has been suggested to
prevent and treat delayed ischemic neurologi-
cal deficit (DIND) in patients after ruptured
aneurysm.
39-41The optimum therapeutic dose of
MgSO4 is unknown, but continuous infusion of
64 mmol/L/ day for 14 days after aneurysmal
surgery has been shown to reduce the risk of
vasospasm  by  34%  and  improve  outcome.
Moreover, MgSO4 infusion which elevates the
serum magnesium concentration to substan-
tial  therapeutic  levels  is  well  tolerated  and
safe, and has no major hemodynamic effects in
patients with DIND.
42-45
When  aggressive  medical  therapy  fails  to
reverse ischemic deficits, prompt endovascular
intervention is indicated.
46 Vasospasm involv-
ing smaller arterial branches may be treated
with an intraarterial infusion of vasodilators.
Intraarterial papaverine is widely used; it pro-
duces clinical improvement in 43% of patients,
augments CBF in another 60% of patients, and
mean TCD velocities are improved. However,
increased intracranial pressure, marked neu-
rological deterioration and other complications
are experienced with this mode of treatment,
reaching  10%  in  some  series.  Overall  supra
selective intraarterial papaverine infusion is
still  highly  recommended.
47-49 Unfortunately,
this  dilatory  effect  tends  to  be  short-lasting
and requires repetition in cases of persistent
vasospasm  to  improve  CBF  and  outcomes.
50
Nicardipine,  another  vasodilating  agent,  has
also  been  trialled.  Endovascular  nicardipine
therapy produced clinical improvement in 42%
of patients, with significant improvement of
mean TCD velocities, but only for four days. It
was recommended as an endovascular treat-
ment protocol for refractory vasospasm but this
requires further evaluation.
46,51
Proximal vasospasm of larger vessels may
be effectively treated with intraluminal balloon
angioplasty. The benefit of this procedure is
durable compared with intraarterial vasodila-
tors.  Clinical  series  assessing  transluminal
balloon angioplasty indicate clinical improve-
ment  in  62%  of  patients,  and  considerably
improved  mean  transcranial  Doppler  (TCD)
velocities and CBF in 85% of patients as stud-
ied by Xenon133 techniques and serial SPECT.
Although it is efficient in treating the artery in
spasm it may cause arterial rupture in 1.1%.
52,53
Controlled  neuro-intensive  management
with endovascular techniques are integrated
in protocols rather than alternative methods
for  the  treatment  of  imminent  vasospasm.
However, poor results are seen in patients with
high clinical grades at the onset of SAH and
advanced age, despite aggressive endovascular
treatment.
25,54,55
Barbiturate-induced coma can be of help in
patients with vasospasm which is refractory to
other  therapies,  to  prevent  life  threatening
neurological deficit. Barbiturates can amelio-
rate  the  harmful  consequences  of  cerebral
ischemia from vasospasm by reducing the neu-
ronal metabolic rate and decreasing O2 con-
sumption. Barbiturate therapy has shown an
improvement in 45% of patients with no relat-
ed deaths reported. Cardiovascular depression
and sepsis are the major concerns for barbitu-
rate use.
56 Pentobarbital sodium is the most
active cerebral vasodilator in this class of anes-
thetics.  This  agent  inhibits  the  vasospastic
activity  of  potassium,  serotonin,  and  prosta-
glandins, and appears to be a calcium entry
antagonist in the blood vessels. Cerebral  per-
fusion pressure should be controlled by the use
of vasopressors to offset the hypotensive effect
of barbiturates.  Barbiturate therapy is contin-
ued as long as vasospasm persists with high
ICP.  Therapeutic  end  point  is  ICP  control.
Following these guidelines, administration of
barbiturates  is  believed  to  achieve  good
results.
57-60
More recently, promising results from the
use of the endothelin A (ETA) receptor antago-
nist clazosentan may create new options for
treatment of CV.
21 Moreover, the probable role
of E-selectin in the pathogenesis of vasospasm
and the use of anti-E-selectin monoclonal anti-
body  may  help  treatment.  Further  trials  are
required to confirm these results.
61
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a
b
Figure 3. (a) CT scan of a 55 year-old man showing a large amount of blood in the sub-
arachnoid space (Fisher grade 3). (b) CT scan of the same patient revealed bifrontal infarc-
tion from severe bilateral ACA vasospasm. Although he had aggressive medical and surgi-
cal treatment for vasospasm he was left with severe disability. References
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